Date: 2015-04-01
Type of information: Nomination
Compound:
Company: Immunogen (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 1, 2015, ImmunoGen announced the appointment of Anna Berkenblit, MD, MMSc, as Vice President and Chief Medical Officer. Dr. Berkenblit reports to Dr. Charles Morris, EVP and Chief Development Officer and is responsible for leading the clinical development of ImmunoGen\'s novel, wholly owned product candidates. Dr. Berkenblit has extensive experience in the clinical development of novel anticancer therapies, including five years heading clinical research at two oncology-focused companies. Prior to joining ImmunoGen, Dr. Berkenblit was Senior Vice President, Clinical Development at H3 Biomedicine, a developer of targeted anticancer compounds founded by Eisai Pharmaceuticals. Prior to H3 Biomedicine, she was VP, Head of Clinical Research at AVEO Oncology, where she led the clinical development of oncology product candidates spanning early testing to registration trials. Prior to AVEO, Dr. Berkenblit held positions of increasing responsibility at Wyeth and then Pfizer, becoming Vice President, Neratinib Asset Team Leader in the Pfizer Oncology Business Unit. Dr. Berkenblit earned an MD degree from Harvard Medical School, and a MMSc degree in the Clinical Investigator Training Program of Harvard/MIT Health Sciences & Technology. She did her internship and residency at Brigham and Women\'s Hospital and a hematology/oncology fellowship at Beth Israel Deaconess Medical Center, where she also ran the Phase I oncology clinical trial program as part of the Dana-Farber/Harvard Cancer Center.
Financial terms:
Latest news:
